Oculis is a biopharmaceutical company focused on neuro-ophthalmology and ophthalmology. Its late-stage clinical pipeline focuses on two core product candidates. Privosegtor and Licaminlimab.

Atinary intends to integrate Chemspeed configurable laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its agentic AI workflows. Bruker acquired ...

The Swiss-Indian agritech startup SUIND has raised around CHF 1.75 million (INR 20.5 crore) in a seed funding round led by Transition VC, with participation from IIMA Ventures. The startup will use ...

Although biotech start-ups stand out with their mega-investments, there are numerous successful start-ups in the life sciences sector centred around pharmaceuticals.

The shareholders of Swiss sovereign cloud provider Infomaniak have signed an agreement for the listing of the company on the SIX Swiss Exchange, through a reverse takeover transaction with Perrot ...

Ensysce Biosciences, a clinical-stage company developing a new class of highly novel opioids for the treatment of severe pain, has acquired Zug-based Cy Biopharma, a clinical-stage biotechnology ...

Zug-based startup AVEA develops science-backed longevity solutions based on the latest scientific research. The company has now brought Olympic gold medallist and two-time halfpipe world champion ...

German Postnova Analytics GmbH has successfully completed the acquisition of LS Instruments AG. The milestone opens new opportunities for innovation, international growth and product development.

FGE NexantECA has completed the acquisition of Morges-based Square Commodities ("SquareCo"), the leading research and data analytics platform specialising in the global renewable fuels market. Founded ...

Vaud-based PeriVision, a University of Bern spin-off, has developed VisionOne, a platform that uses virtual reality glasses to measure the impact of glaucoma on visual fields – information that is ...

Around 450 startups applied for this year's >>venture>> award—more than any previous edition. Three finalists in each of six verticals will pitch for the 2026 Grand Prize, worth CHF 150,000. Three ...

Basel-based Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152 million ...